No black box warning on record for Tyenne

As of the latest FDA labeling reviewed, Tyenne (TOCILIZUMAB-AAZG) does not carry a black box warning. Standard warnings and precautions still apply — see the full Tyenne medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Serious Infections – do not administer TYENNE during an active infection, including localized infections. If a serious infection develops, interrupt TYENNE until the infection is controlled. ( 5.1 ) • Gastrointestinal (GI) perforation-use with caution in patients who may be at increased risk. ( 5.2 ) • Hepatotoxicity- Monitor patients for signs and symptoms of hepatic

No black box warning on record for Tyenne

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Serious Infections – do not administer TYENNE during an active infection, including localized infections. If a serious infection develops, interrupt TYENNE until the infection is controlled. ( 5.1 ) • Gastrointestinal (GI) perforation-use with caution in patients who may be at increased risk. ( 5.2 ) • Hepatotoxicity- Monitor patients for signs and symptoms of hepatic

Tyenne Black Box Warning

No black box warning on record for Tyenne

Other warnings & precautions

Tyenne Black Box Warning

No black box warning on record for Tyenne

Other warnings & precautions